Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.3149
+0.0059 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
929,907
Open
0.3179
Bid (Size)
0.3146 (7)
Ask (Size)
0.3180 (1)
Prev. Close
0.3090
Today's Range
0.3090 - 0.3198
52wk Range
0.3020 - 1.250
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
August 29, 2024
Via
Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s
From
23andMe, Inc.
Via
GlobeNewswire
Performance
YTD
-65.33%
-65.33%
1 Month
-21.28%
-21.28%
3 Month
-42.24%
-42.24%
6 Month
-42.15%
-42.15%
1 Year
-71.37%
-71.37%
More News
Read More
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
August 08, 2024
Via
InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
August 08, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
June 12, 2024
Via
Benzinga
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
August 02, 2024
Via
InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
August 02, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
August 01, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024
From
23andMe, Inc.
Via
GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
July 24, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
July 19, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
July 11, 2024
Via
InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
June 28, 2024
From
23andMe, Inc.
Via
GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
June 27, 2024
Via
The Motley Fool
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
June 11, 2024
Via
InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
June 05, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
June 04, 2024
Via
The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
June 04, 2024
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
June 03, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
May 29, 2024
From
23andMe, Inc.
Via
GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
May 23, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
May 23, 2024
Via
Benzinga
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
May 23, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.